Effect on lipoproteins of Trisequens, a combined hormone preparation.
Lipoprotein concentrations were measured in 31 post-menopausal women during 1 yr of treatment with Trisequens, a natural oestrogen-progestogen preparation. Serum triglyceride, high density lipoprotein and very low density lipoprotein cholesterol concentrations did not change significantly, but low density lipoprotein cholesterol concentrations fell over the first 6 mth. After 1 yr none of the lipoprotein fractions differed significantly in concentration from pre-treatment levels.
D000328:Adult; D002369:Castration; D002784:Cholesterol / Q000097:blood*; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D015243:Cholesterol, VLDL; D003327:Coronary Disease / Q000097:blood; D004338:Drug Combinations / Q000494:pharmacology / Q000627:therapeutic use; D004958:Estradiol / Q000494:pharmacology* / Q000627:therapeutic use; D004964:Estriol / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008074:Lipoproteins / Q000097:blood*; D008079:Lipoproteins, VLDL / Q000097:blood; D008593:Menopause; D008875:Middle Aged; D009640:Norethindrone / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D012306:Risk; D014280:Triglycerides / Q000097:blood
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D015243:Cholesterol, VLDL; D004338:Drug Combinations; D008074:Lipoproteins; D008079:Lipoproteins, VLDL; D014280:Triglycerides; D004958:Estradiol; C032040:Trisequens; D002784:Cholesterol; D004964:Estriol; D009640:Norethindrone